The central focus of the Cytogenetics Shared Resource (CSR) is to provide cytogenetic and molecular cytogenetic analysis of human and animal model research samples. These samples may be in the form of cultured cells, fresh or frozen tissue, paraffin-embedded sections, or tissue microarrays (TMAs). Specific cell types include tumor cell lines, xenograft cells, hybrid cells from chimeric animal models, neural stem cells, and mouse embryonic fibroblasts, among others. The CSR provides specialized services including cell culture, routine cytogenetic analysis, chromosome breakage analysis, interphase and metaphase Fluorescence in situ Hybridization (FISH), Spectral Karyotyping (SKY) analysis of human and mouse metaphases, and homebrew FISH Probe Production. This last service provides novel FISH probes that are specific to investigators needs and are usually not commercially available. These probes are then used for FISH analysis studies. The CSR is expanding this service beyond homebrew enumeration FISH probes by creating custom translocation/fusion probes, break-apart probes, and multi-color FISH probes to ultimately assist in developing strategic probes that become clinical diagnostic and prognostic markers of disease. Other services provided by the CSR to meet the needs of investigators include utilization of the CSR laboratory for slide processing and fluorescent microscope and imaging system use. Briefly, applications of CSR services include: to characterize the clonality of tumor specimens;to determine the origin of a specific tumor culture (i.e., mouse vs. human), to aid in the identification of genetic regions important for the development of specific malignancies, and to map the location of DMA sequences, genes, or transgene insertions. With the recognition that cancer is a genetic disease, many cancer researchers, including scientists in the Mayo Clinic Cancer Center (MCCC), require access to CSR services. This Shared Resource is utilized by 9 of the 12 Cancer Center Programs. Approximately 66% of CSR users are CCSG members and represent 92% of the overall utilization.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015083-39
Application #
8465658
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-03-01
Budget End
2014-02-28
Support Year
39
Fiscal Year
2013
Total Cost
$92,053
Indirect Cost
$28,324
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Basch, Ethan; Rogak, Lauren J; Dueck, Amylou C (2016) Methods for Implementing and Reporting Patient-reported Outcome (PRO) Measures of Symptomatic Adverse Events in Cancer Clinical Trials. Clin Ther 38:821-30
Renner, Danielle N; Malo, Courtney S; Jin, Fang et al. (2016) Improved Treatment Efficacy of Antiangiogenic Therapy when Combined with Picornavirus Vaccination in the GL261 Glioma Model. Neurotherapeutics 13:226-36
Navari, Rudolph M; Qin, Rui; Ruddy, Kathryn J et al. (2016) Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting. N Engl J Med 375:134-42
Amirian, E Susan; Zhou, Renke; Wrensch, Margaret R et al. (2016) Approaching a Scientific Consensus on the Association between Allergies and Glioma Risk: A Report from the Glioma International Case-Control Study. Cancer Epidemiol Biomarkers Prev 25:282-90
Cuellar-Partida, Gabriel; Lu, Yi; Dixon, Suzanne C et al. (2016) Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. Hum Genet 135:741-56
Ye, Zi; Austin, Erin; Schaid, Daniel J et al. (2016) A multi-locus genetic risk score for abdominal aortic aneurysm. Atherosclerosis 246:274-9
McCormack, Valerie A; Burton, Anya; dos-Santos-Silva, Isabel et al. (2016) International Consortium on Mammographic Density: Methodology and population diversity captured across 22 countries. Cancer Epidemiol 40:141-51
Basal, E; Ayeni, T; Zhang, Q et al. (2016) Patterns of Müllerian Inhibiting Substance Type II and Candidate Type I Receptors in Epithelial Ovarian Cancer. Curr Mol Med 16:222-31
Vaidhyanathan, Shruthi; Wilken-Resman, Brynna; Ma, Daniel J et al. (2016) Factors Influencing the Central Nervous System Distribution of a Novel Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor GSK2126458: Implications for Overcoming Resistance with Combination Therapy for Melanoma Brain Metastases. J Pharmacol Exp Ther 356:251-9
Yoon, H H; Foster, N R; Meyers, J P et al. (2016) Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (alliance). Ann Oncol 27:339-44

Showing the most recent 10 out of 948 publications